Treatment responder analysis in actinic keratosis: can it lead the way to individualized choice of treatment?
actinic keratosis
diclofenac sodium
individualized treatment approach
ingenol mebutate
responder analysis
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
31
8
2019
medline:
23
6
2021
entrez:
31
8
2019
Statut:
ppublish
Résumé
It is unclear if there are any distinct AK patient populations that might respond best to a given treatment. To identify if a distinct subgroup of patients with AK might respond better to treatment with ingenol mebutate (IngMeb) versus diclofenac sodium (DS). Complete clearance of AK and mean lesion reduction at end of first treatment course and week 17 were evaluated within subgroups. 502 patients (255 IngMeb; 247 DS) were included in the analysis. At week 17, complete clearance was achieved by more patients treated with IngMeb versus DS within the majority of patient subgroups, including patients with <6 lesions and ≥6 lesions at baseline, aged ≥65 years, males, females, Fitzpatrick skin types II and III, and facial lesions. Mean lesion reduction at week 17 was greater with IngMeb than DS within the same subgroups, and in patients with scalp lesions. This responder analysis did not identify any distinct population that responded more optimally than others with IngMeb or DS. More patients achieved complete clearance and higher lesion reduction of AK with IngMeb compared with DS in most subgroups.
Sections du résumé
BACKGROUND
BACKGROUND
It is unclear if there are any distinct AK patient populations that might respond best to a given treatment.
OBJECTIVE
OBJECTIVE
To identify if a distinct subgroup of patients with AK might respond better to treatment with ingenol mebutate (IngMeb) versus diclofenac sodium (DS).
METHODS
METHODS
Complete clearance of AK and mean lesion reduction at end of first treatment course and week 17 were evaluated within subgroups.
RESULTS
RESULTS
502 patients (255 IngMeb; 247 DS) were included in the analysis. At week 17, complete clearance was achieved by more patients treated with IngMeb versus DS within the majority of patient subgroups, including patients with <6 lesions and ≥6 lesions at baseline, aged ≥65 years, males, females, Fitzpatrick skin types II and III, and facial lesions. Mean lesion reduction at week 17 was greater with IngMeb than DS within the same subgroups, and in patients with scalp lesions.
CONCLUSIONS
CONCLUSIONS
This responder analysis did not identify any distinct population that responded more optimally than others with IngMeb or DS. More patients achieved complete clearance and higher lesion reduction of AK with IngMeb compared with DS in most subgroups.
Identifiants
pubmed: 31469026
doi: 10.1080/09546634.2019.1662879
doi:
Substances chimiques
3-ingenyl angelate
0
Diterpenes
0
Diclofenac
144O8QL0L1
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM